BioSpace News Archive

Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the third quarter 2022 after market close on November 3, 2022.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022.

Prothena Corporation plc (NASDAQ:PRTA) today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.

XtalPi, Inc., a privately-held solution provider accelerating biopharmaceutical research via its integrated technology platform, announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) to deliver chemical matter with validated binding affinities and desirable property profiles.

Akebia Therapeutics, Inc. today announced plans to release its financial results for the third quarter ended September 30, 2022 on Thursday, November 3, 2022 following the close of financial markets.

According to Vision Research Reports, the global retinal vein occlusion treatment market size is expected to surpass around USD 34.88 billion by 2030 and poised to grow at a CAGR of 7.42% from 2022 to 2030.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 2022.

Acadia Pharmaceuticals Inc. announced that its President, Srdjan Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced that it has initiated the LYNX Phase 2 clinical trial at Rare Disease Research, LLC in Atlanta, Georgia.

The global Genomics market size was estimated at USD 27.90 billion in 2021 and is expected to surpass around USD 96.25 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 20.9% during the forecast period 2022 to 2030.